News Astellas Pharma Inc. OTC Markets

Stocks

ALPMY

US04623U1025

Pharmaceuticals

Market Closed - OTC Markets 15:55:40 2026-11-13 EST			5-day change	1st Jan Change
16.84 ^USD	+2.03%		+6.48%	+26.75%

11-11	HEALTH ROUNDS-New blood test finds early risk for ovarian cancer	RE
11-07	Astellas employee imprisoned in China to be released in December, Japanese media report	RE

All News

Mentions Relevance

2bd.4pyYa6yKV1mQPuC0KZOEIVb69vjB-g6V_K-YfbZNBfk.q9v8WIHrIQbTCL-ARvT0dRjMpauRiHvnqZboO44eY5ugrtIF-Lk4D9hQiw

11-07	Astellas employee imprisoned in China to be released in December, Japanese media report	RE
11-04	Astellas Pharma Logs Higher Fiscal H1 Attributable Core Profit; Revenue Up	MT
11-04	Astellas Pharma Inc. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2027; Announces Dividend for the Second Quarter Ended September 30, 2026, Payable on December 1, 2026	CI
11-04	Astellas Pharma Inc. Provides Consolidated Earnings Guidance for Fiscal Year Ending March 31, 2027	CI
11-04	Astellas Pharma Inc. Reports Earnings Results for the Half Year Ended September 30, 2026	CI
10-28	Astellas Pharma Inc. Enters Exclusive Option and License Agreement with Audax Biosciences Pty Ltd for Dax-044	CI
09-24	Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D- Mutated Advanced Non-Small Cell Lung Cancer	AQ
09-23	Astellas Pharma Inc. Doses First Patient In Phase 3 Study Of Setidegrasib In Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer	CI
09-16	Astellas Pharma Inc. Announces Executive Changes	CI
08-31	Astellas Pharma Inc. Enters Voluntary Agreement with U.S. Government Supporting Affordable Access to Medicines	CI
08-27	Astellas' Profits May Have Doubled, But Can It Outrun the Street's Skepticism?
08-24	Astellas Pharma Inc. Doses First Patient In Phase 3 Study Of ASP2138 In Combination With Chemotherapy And Pembrolizumab As First-Line Treatment In Adults With Locally Advanced Unresectable Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma	CI
08-17	CLSA Starts Astellas Pharma at Accumulate with 3,000 Yen Price Target	MT
08-10	AbCellera's menopause drug cuts hot flashes in mid-stage trial, shares surge	RE
08-06	South African Patent Ruling In Favour Of Astellas Pharma	AQ
08-05	Japan Earnings Wrap: Kao, Astellas Pharma Rise; Taiyo Yuden Declines	MT
08-05	Astellas Pharma's Profit Soars 107% in Fiscal Q1	MT
08-05	Astellas Pharma Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
07-12	Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug	MT
06-30	Trump's push for the world's lowest drug prices hits snag with mid-sized companies	RE
06-23	China detains two Japanese nationals suspected of smuggling banned goods	RE
06-04	Astellas Pharma Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 08:10 AM
06-03	Astellas Pharma Inc. - Special Call
05-29	Astellas Pharma Inc. Announces Resignation of Andreas Busch, an Outside Director from His Position as Director Effective May 29, 2026	CI
05-29	Astellas Pharma: Institutional Shareholder Services has issued a report recommending a vote against a director candidate	RE